Financial Results and Updates - TuHURA Biosciences reported financial results for Q1 2025, with a focus on corporate updates[7]. - TuHURA's financial condition and operational results are detailed in the press release dated May 15, 2025[7]. - The company has not undertaken any obligation to update forward-looking statements unless required by securities laws[14]. Acquisition and Merger - The company is in the process of acquiring Kineta, Inc., with a registration statement filed on February 7, 2025[8]. - The merger with Kineta is expected to enhance TuHURA's capabilities in tumor microenvironment modulators[13]. - TuHURA is actively seeking additional capital to support the Kineta merger and its ongoing development programs[13]. - The company emphasizes the importance of reading the Joint Proxy Statement/Prospectus for detailed information regarding the merger[9]. Product Development - TuHURA's product candidate IFx-Hu2.0 is anticipated to enter Phase 3 trials, indicating progress in its development pipeline[13]. - The anticipated regulatory pathway and timing for TuHURA's development programs are outlined as part of their forward-looking statements[13]. Stock Information - TuHURA's stock is traded on The Nasdaq Capital Market under the symbol HURA[5].
Kintara Therapeutics(KTRA) - 2025 Q3 - Quarterly Results